Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
The SGLT2 inhibitor treatment appeared to be cost-effective for the overall population of our study and particularly for younger patients (<70 years old). For older patients (≥70 years old), the cost-effectiveness was less clear and may require further evaluation. Decision-makers should consider this age-based heterogeneity when making recommendations about SGLT2 inhibitor treatment.
Authors
- Eiko Saito (ORCID: https://orcid.org/0000-0002-4550-9631)
- Shun Kohsaka (ORCID: https://orcid.org/0000-0003-3779-2972)
- Keiko Maruyama‐Sakurai (ORCID: https://orcid.org/0000-0001-6100-2227)
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Hisateru Tachimori (ORCID: https://orcid.org/0000-0001-6401-2885)
- Hiroaki Miyata (ORCID: https://orcid.org/0000-0001-8800-6201)
- Yasumasa Segawa
Institutions
- Keio University (JP)
- University of Tokyo Health Sciences (JP)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1111/dom.15832
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- Mitsubishi Tanabe Pharma Corporation